CME: Rheumatoid Arthritis (RA): Therapeutic Updates, Best Practices, and Barriers to Care
ACCREDITATION EXPIRED: August 21, 2016
Activity Description / Statement of Need:
In this online CME self-learning program:
Rheumatoid arthritis (RA) is a systemic autoimmune disorder in which joints, typically those in the hands and feet, become inflamed, swollen, painful, and stiff. Without appropriate treatment, the inflammation may become chronic and cause irreversible destruction of bone and cartilage in the affected joints as well as contribute to the development of clinically important co-morbid conditions with attendant morbidity and mortality. The National Arthritis Data Workgroup estimates that about 1.3 million U.S. adults (0.6% of the adult population) have RA. RA imposes a considerable disease burden. Patients with RA have substantially lower health-related quality of life (QOL) than the general population with lower overall scores for physical and mental health across all age groups. The RA disease burden also is associated with increased health care resource utilization. Notably, RA patients with low QOL are twice as likely to be hospitalized as RA patients with high QOL.
The revised 2010 ACR/European League Against Rheumatism (EULAR) Diagnostic Criteria for Rheumatoid Arthritis expanded the number of potential patients eligible for RA treatment. Moreover, guidelines governing the treatment of RA have been updated fairly recently. The literature suggests that practicing healthcare professionals are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice, and awareness of professional guidelines is no exception. Recently published guidelines therefore also inherently suggest a gap in medical practice and justify the need for educational programming.
Agenda
|
Updates in epidemiology and risk factors for RA
|
|
Updates in clinical Presentation and diagnosis of Rheumatoid Arthritis
|
|
Treatment in patients with Rheumatoid Arthritis •The latest evidence and guidelines
|
|
Barrier to Optimal Care in Patients with Rheumatoid Arthritis
|
Target Audience:
Healthcare professionals specializing in rheumatology, family medicine, geriatrics, internal medicine, primary care, public health, or those who otherwise commonly care for individuals with RA.
This program is supported by an educational grant from Questcor.
Release Date: August 21, 2014 -- Expiration Date: August 21, 2016
Faculty: Peng Fan, MD
Agenda
Learning Objectives
By the end of the session the participant will be able to:
- Recognize and describe those characteristics that play a role in determining the staging, prognosis, and diagnosis of RA.
- Distinguish between the most appropriate treatment approaches to RA and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them
- Distinguish between the most appropriate treatment approaches to RA and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
- Summarize the risk-benefit profiles of current and emerging therapies for the treatment of RA
- Describe the challenges and barriers to care associated with treating patients with RA.
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dr. Fan, MD, discloses that he is a consultant/ speaker for : AMGEN, Pfizer, Genentech, MBS, & Abbvie.
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC with no relevent financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Questcor.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.